Prostate Cancer Clinical Trial
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Summary
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
Full Description
RADICAL PC describes two prospective studies, one of which is embedded in the other. RADICAL PC1 is a prospective cohort study of men within one year of their first diagnosis of prostate cancer, or treated with Androgen Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation Therapy for the first time within one month after the enrollment visit. Its goal will be to identify factors associated with the development of cardiovascular disease among men with prostate cancer, with a particular focus on Androgen Deprivation Therapy. RADICAL PC2 is a randomized, controlled trial embedded in RADICAL PC1. RADICAL PC2 will test a systematic approach to modifying cardiovascular and lifestyle risk factors in men within one year of their first diagnosis of prostate cancer, or treated with Androgen Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation Therapy for the first time within one month after the enrollment visit.
Eligibility Criteria
Inclusion Criteria:
1. A man with a diagnosis of prostate cancer that is either:
new (i.e. the diagnosis was made within 1 year of the enrolment visit) or
treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or
to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit
Exclusion Criteria:
Patients will be excluded if they fulfill any of the following:
are unwilling to provide consent or
are <45 years of age, or
prostate cancer was found incidentally following cystectomy for bladder cancer
Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
see a cardiologist every year, or
both take a statin and have systolic blood pressure ≤130mmHg
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 48 Locations for this study
Augusta Georgia, 30912, United States More Info
Principal Investigator
Kansas City Kansas, 66160, United States More Info
Principal Investigator
Waratah New South Wales, 2298, Australia More Info
Principal Investigator
Westmead New South Wales, 2145, Australia More Info
Principal Investigator
Adelaide South Australia, 5000, Australia More Info
Principal Investigator
Adelaide South Australia, 5042, Australia More Info
Principal Investigator
Brasilia DF, 71625, Brazil More Info
Principal Investigator
Belo Horizonte Minas Gerais, 30110, Brazil More Info
Principal Investigator
Uberaba Minas Gerais, 38025, Brazil More Info
Principal Investigator
Campina Grande Do Sul Paraná, 83.43, Brazil More Info
Principal Investigator
Campo Largo Paraná, , Brazil More Info
Principal Investigator
Curitiba Paraná, 80810, Brazil More Info
Principal Investigator
Recife Pernambuco, 50.07, Brazil More Info
Principal Investigator
Ijuí Rio Grande Do Sul, 98700, Brazil More Info
Principal Investigator
Porto Alegre Rio Grande Do Sul, 90035, Brazil More Info
Principal Investigator
Porto Alegre Rio Grande Do Sul, 90050, Brazil More Info
Principal Investigator
Porto Alegre Rio Grande Do Sul, 90840, Brazil More Info
Principal Investigator
Botucatu São Paulo, 18618, Brazil More Info
Principal Investigator
Bragança Paulista São Paulo, 12.91, Brazil More Info
Principal Investigator
Jaú São Paulo, 17210, Brazil More Info
Principal Investigator
São José Do Rio Preto São Paulo, 15090, Brazil More Info
Principal Investigator
Votuporanga São Paulo, 15501, Brazil More Info
Principal Investigator
Rio De Janeiro , 22240, Brazil
São Paulo , 01223, Brazil More Info
Principal Investigator
São Paulo , 02189, Brazil More Info
Principal Investigator
São Paulo , 05403, Brazil More Info
Principal Investigator
São Paulo , 08270, Brazil More Info
Principal Investigator
São Paulo , 45430, Brazil More Info
Principal Investigator
Vancouver British Columbia, V5Z 1, Canada
Hamilton Ontario, L8N4A, Canada More Info
Principal Investigator
Hamilton Ontario, L8V1C, Canada More Info
Principal Investigator
Kingston Ontario, K7L 3, Canada More Info
Principal Investigator
Kitchener Ontario, N2G 1, Canada More Info
Principal Investigator
London Ontario, N6A 5, Canada More Info
Principal Investigator
London Ontario, N6A 5, Canada More Info
Principal Investigator
Niagara Ontario, L2S 0, Canada More Info
Principal Investigator
Ottawa Ontario, K1H 8, Canada More Info
Principal Investigator
Toronto Ontario, M4N 3, Canada More Info
Principal Investigator
Toronto Ontario, M5G 2, Canada
Montreal Quebec, H2X 0, Canada More Info
Principal Investigator
Montreal Quebec, H3T 1, Canada More Info
Principal Investigator
Montréal Quebec, H1T 2, Canada More Info
Principal Investigator
Montréal Quebec, H3A 0, Canada More Info
Principal Investigator
Quebec City Quebec, G1V 0, Canada More Info
Principal Investigator
Sherbrooke Quebec, J1H 5, Canada More Info
Principal Investigator
Bogotá Cundinamarca, , Colombia More Info
Principal Investigator
Cali Valle Del Cauca, , Colombia More Info
Principal Investigator
Holon , 58406, Israel More Info
Sub-Investigator
Tel Aviv , 64239, Israel More Info
Principal Investigator
Istanbul , , Turkey
How clear is this clinincal trial information?